Goodwin Completes Areva Conjugate Mfg.

Goodwin Biotechnology Inc. (GBI) has completed the cGMP manufacturing and vialing of Areva Med’s monoclonal antibody-chelator conjugate. As part of Areva Med’s Lead-212 (212Pb) initiative, the conjugate will be used in Phase I clinical trials to treat several types of deadly forms of cancers.

David Fischer, executive vice president of GBI, said, “We are very pleased to have completed the manufacturing of AREVA Med’s conjugate. After some promising preclinical data, we look forward to seeing the outcome of the first-in-man studies.”